Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2

Affiliations

• ¹ Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics, University of California Los Angeles, Los Angeles, Calif.
• ² Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, Calif; California NanoSystems Institute, University of California Los Angeles, Los Angeles, Calif.
• ³ Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, Calif; Division of Infectious Diseases, Department of Pediatrics, University of California Los Angeles, Los Angeles, Calif.
• ⁴ Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, Calif; California NanoSystems Institute, University of California Los Angeles, Los Angeles, Calif; Department of Bioengineering, Samueli School of Engineering, University of California Los Angeles, Los Angeles, Calif.
• ⁵ Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics, University of California Los Angeles, Los Angeles, Calif; Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, Calif. Electronic address: mbutte@mednet.ucla.edu.